Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 1722 entries
Sorted by: Best Match Show Resources per page
Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed

veteran

Fonda JR.
GSID: EVNwZIVjkmYJ
JA Hermos, MM Young, JR Fonda… - Clinical infectious …, 2012 - academic.oup.com

… Accordingly, we studied PPI exposure and CAP in veteran patients, using a retrospective, … We believed that veteran patients, frequently burdened by chronic medical conditions, would …

Cite
Hermos, J. A., Young, M. M., Fonda, J. R., Gagnon, D. R., Fiore, L. D., & Lawler, E. V. (2012). Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed. Clinical infectious diseases, 54(1), 33-42.
Hermos, John A., et al. "Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed." Clinical infectious diseases 54.1 (2012): 33-42.
Copy Download .nbib Format: MLA
Daytime intragastric acid control: post hoc analyses of esomeprazole 20 mg and over-the-counter proton-pump inhibitors.

Therapeutic advances in gastroenterology

Katz P, Kahrilas PJ, Johnson DA, Lind T, Röhss K, Traxler B, Hugo V, Dent J.
PMID: 26557888
Therap Adv Gastroenterol. 2015 Nov;8(6):322-30. doi: 10.1177/1756283X15592583.

OBJECTIVES: In mild gastroesophageal reflux disease, which accounts for the great majority of cases, the major burden of reflux occurs during daytime hours, after food intake. The aim of these analyses was to evaluate intragastric pH control during the...

Cite
Katz P, Kahrilas PJ, Johnson DA, et al. Daytime intragastric acid control: post hoc analyses of esomeprazole 20 mg and over-the-counter proton-pump inhibitors. Therap Adv Gastroenterol. 2015;8(6):322-30doi: 10.1177/1756283X15592583.
Katz, P., Kahrilas, P. J., Johnson, D. A., Lind, T., Röhss, K., Traxler, B., Hugo, V., & Dent, J. (2015). Daytime intragastric acid control: post hoc analyses of esomeprazole 20 mg and over-the-counter proton-pump inhibitors. Therapeutic advances in gastroenterology, 8(6), 322-30. https://doi.org/10.1177/1756283X15592583
Katz, Philip, et al. "Daytime intragastric acid control: post hoc analyses of esomeprazole 20 mg and over-the-counter proton-pump inhibitors." Therapeutic advances in gastroenterology vol. 8,6 (2015): 322-30. doi: https://doi.org/10.1177/1756283X15592583
Katz P, Kahrilas PJ, Johnson DA, Lind T, Röhss K, Traxler B, Hugo V, Dent J. Daytime intragastric acid control: post hoc analyses of esomeprazole 20 mg and over-the-counter proton-pump inhibitors. Therap Adv Gastroenterol. 2015 Nov;8(6):322-30. doi: 10.1177/1756283X15592583. PMID: 26557888; PMCID: PMC4622284.
Copy Download .nbib Format: NLM
Updates on endoscopic therapy of esophageal carcinoma.

Thoracic cancer

Isomoto H.
PMID: 28920293
Thorac Cancer. 2012 May;3(2):125-130. doi: 10.1111/j.1759-7714.2012.00109.x.

Endoscopic submucosal dissection (ESD) has the advantage over endoscopic mucosa resection (EMR), permitting removal of gastrointestinal neoplasms en bloc, but is associated with a relatively high risk of complications. Early esophageal cancer (EEC) is indicated when the tumors are...

Cite
Isomoto H. Updates on endoscopic therapy of esophageal carcinoma. Thorac Cancer. 2012;3(2):125-130doi: 10.1111/j.1759-7714.2012.00109.x.
Isomoto, H. (2012). Updates on endoscopic therapy of esophageal carcinoma. Thoracic cancer, 3(2), 125-130. https://doi.org/10.1111/j.1759-7714.2012.00109.x
Isomoto, Hajime. "Updates on endoscopic therapy of esophageal carcinoma." Thoracic cancer vol. 3,2 (2012): 125-130. doi: https://doi.org/10.1111/j.1759-7714.2012.00109.x
Isomoto H. Updates on endoscopic therapy of esophageal carcinoma. Thorac Cancer. 2012 May;3(2):125-130. doi: 10.1111/j.1759-7714.2012.00109.x. PMID: 28920293.
Copy Download .nbib Format: NLM
Sevelamer carbonate reduces the risk of hypomagnesemia in hemodialysis-requiring end-stage renal disease patients.

Clinical kidney journal

Rosa-Diez G, Negri AL, Crucelegui MS, Philippi R, Perez-Teysseyre H, Sarabia-Reyes C, Loor-Navarrete H, Heguilen R.
PMID: 27274837
Clin Kidney J. 2016 Jun;9(3):481-5. doi: 10.1093/ckj/sfw021. Epub 2016 Apr 14.

BACKGROUND: Sevelamer has been associated with less progression of vascular calcifications. This effect could be due to a reduction in serum phosphate levels but also to other additive effects. Magnesium has been also shown to prevent vascular calcification but...

Cite
Rosa-Diez G, Negri AL, Crucelegui MS, et al. Sevelamer carbonate reduces the risk of hypomagnesemia in hemodialysis-requiring end-stage renal disease patients. Clin Kidney J. 2016;9(3):481-5doi: 10.1093/ckj/sfw021.
Rosa-Diez, G., Negri, A. L., Crucelegui, M. S., Philippi, R., Perez-Teysseyre, H., Sarabia-Reyes, C., Loor-Navarrete, H., & Heguilen, R. (2016). Sevelamer carbonate reduces the risk of hypomagnesemia in hemodialysis-requiring end-stage renal disease patients. Clinical kidney journal, 9(3), 481-5. https://doi.org/10.1093/ckj/sfw021
Rosa-Diez, Guillermo, et al. "Sevelamer carbonate reduces the risk of hypomagnesemia in hemodialysis-requiring end-stage renal disease patients." Clinical kidney journal vol. 9,3 (2016): 481-5. doi: https://doi.org/10.1093/ckj/sfw021
Rosa-Diez G, Negri AL, Crucelegui MS, Philippi R, Perez-Teysseyre H, Sarabia-Reyes C, Loor-Navarrete H, Heguilen R. Sevelamer carbonate reduces the risk of hypomagnesemia in hemodialysis-requiring end-stage renal disease patients. Clin Kidney J. 2016 Jun;9(3):481-5. doi: 10.1093/ckj/sfw021. Epub 2016 Apr 14. PMID: 27274837; PMCID: PMC4886916.
Copy Download .nbib Format: NLM
'Lemonade Legs': Why do Some Patients Get Profound Hypomagnesaemia on Proton-Pump Inhibitors?.

Intestinal research

Atkinson NS, Reynolds DJ, Travis SP.
PMID: 26130997
Intest Res. 2015 Jul;13(3):227-32. doi: 10.5217/ir.2015.13.3.227. Epub 2015 Jun 09.

Proton pump inhibitors (PPIs) are widely used though an association with hypomagnesaemia and hypocalcaemia has only been described since 2006. Patients typically present after years of stable dosing with musculoskeletal, neurological or cardiac arrhythmic symptoms, but it is likely...

Cite
Atkinson NS, Reynolds DJ, Travis SP. 'Lemonade Legs': Why do Some Patients Get Profound Hypomagnesaemia on Proton-Pump Inhibitors?. Intest Res. 2015;13(3):227-32doi: 10.5217/ir.2015.13.3.227.
Atkinson, N. S., Reynolds, D. J., & Travis, S. P. (2015). 'Lemonade Legs': Why do Some Patients Get Profound Hypomagnesaemia on Proton-Pump Inhibitors?. Intestinal research, 13(3), 227-32. https://doi.org/10.5217/ir.2015.13.3.227
Atkinson, Nathan S S, et al. "'Lemonade Legs': Why do Some Patients Get Profound Hypomagnesaemia on Proton-Pump Inhibitors?." Intestinal research vol. 13,3 (2015): 227-32. doi: https://doi.org/10.5217/ir.2015.13.3.227
Atkinson NS, Reynolds DJ, Travis SP. 'Lemonade Legs': Why do Some Patients Get Profound Hypomagnesaemia on Proton-Pump Inhibitors?. Intest Res. 2015 Jul;13(3):227-32. doi: 10.5217/ir.2015.13.3.227. Epub 2015 Jun 09. PMID: 26130997; PMCID: PMC4479737.
Copy Download .nbib Format: NLM
Proton pump inhibitor prescribing patterns in newborns and infants.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG

Illueca M, Alemayehu B, Shoetan N, Yang H.
PMID: 25762873
J Pediatr Pharmacol Ther. 2014 Oct-Dec;19(4):283-7. doi: 10.5863/1551-6776-19.4.283.

OBJECTIVES: In 2011, the Food and Drug Administration (FDA) approved intravenous esomeprazole 0.5 mg/day for children aged >1 month and oral esomeprazole for infants aged 1 month to

Cite
Illueca M, Alemayehu B, Shoetan N, et al. Proton pump inhibitor prescribing patterns in newborns and infants. J Pediatr Pharmacol Ther. 2014;19(4):283-7doi: 10.5863/1551-6776-19.4.283.
Illueca, M., Alemayehu, B., Shoetan, N., & Yang, H. (2014). Proton pump inhibitor prescribing patterns in newborns and infants. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 19(4), 283-7. https://doi.org/10.5863/1551-6776-19.4.283
Illueca, Marta, et al. "Proton pump inhibitor prescribing patterns in newborns and infants." The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG vol. 19,4 (2014): 283-7. doi: https://doi.org/10.5863/1551-6776-19.4.283
Illueca M, Alemayehu B, Shoetan N, Yang H. Proton pump inhibitor prescribing patterns in newborns and infants. J Pediatr Pharmacol Ther. 2014 Oct-Dec;19(4):283-7. doi: 10.5863/1551-6776-19.4.283. PMID: 25762873; PMCID: PMC4341413.
Copy Download .nbib Format: NLM
Dexlansoprazole - a new-generation proton pump inhibitor.

Przeglad gastroenterologiczny

Skrzydło-Radomańska B, Radwan P.
PMID: 26759624
Prz Gastroenterol. 2015;10(4):191-6. doi: 10.5114/pg.2015.56109. Epub 2015 Dec 16.

Dexlansoprazole modified release (MR) is an R-enantiomer of lansoprazole and a new-generation proton pump inhibitor exhibiting high efficacy in the treatment of symptoms and lesions associated with erosive oesophagitis caused by gastroesophageal reflux disease (GERD). The dual release of...

Cite
Skrzydło-Radomańska B, Radwan P. Dexlansoprazole - a new-generation proton pump inhibitor. Prz Gastroenterol. 2015;10(4):191-6doi: 10.5114/pg.2015.56109.
Skrzydło-Radomańska, B., & Radwan, P. (2015). Dexlansoprazole - a new-generation proton pump inhibitor. Przeglad gastroenterologiczny, 10(4), 191-6. https://doi.org/10.5114/pg.2015.56109
Skrzydło-Radomańska, Barbara, and Radwan, Piotr. "Dexlansoprazole - a new-generation proton pump inhibitor." Przeglad gastroenterologiczny vol. 10,4 (2015): 191-6. doi: https://doi.org/10.5114/pg.2015.56109
Skrzydło-Radomańska B, Radwan P. Dexlansoprazole - a new-generation proton pump inhibitor. Prz Gastroenterol. 2015;10(4):191-6. doi: 10.5114/pg.2015.56109. Epub 2015 Dec 16. PMID: 26759624; PMCID: PMC4697039.
Copy Download .nbib Format: NLM
Esophagogastric Junction Contractility Integral Reflect the Anti-reflux Barrier Dysfunction in Patients with Gastroesophageal Reflux Disease.

Journal of neurogastroenterology and motility

Xie C, Wang J, Li Y, Tan N, Cui Y, Chen M, Xiao Y.
PMID: 27426485
J Neurogastroenterol Motil. 2017 Jan 30;23(1):27-33. doi: 10.5056/jnm16008.

BACKGROUND/AIMS: Anti-reflux barrier dysfunction is one of the primary mechanisms in gastroesophageal reflux disease (GERD) pathogenesis. The esophagogastric junction contractile integral (EGJ-CI) is a new metric adopted to evaluate the EGJ contractility, which implies the antireflux barrier function. The...

Cite
Xie C, Wang J, Li Y, et al. Esophagogastric Junction Contractility Integral Reflect the Anti-reflux Barrier Dysfunction in Patients with Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2017;23(1):27-33doi: 10.5056/jnm16008.
Xie, C., Wang, J., Li, Y., Tan, N., Cui, Y., Chen, M., & Xiao, Y. (2017). Esophagogastric Junction Contractility Integral Reflect the Anti-reflux Barrier Dysfunction in Patients with Gastroesophageal Reflux Disease. Journal of neurogastroenterology and motility, 23(1), 27-33. https://doi.org/10.5056/jnm16008
Xie, Chenxi, et al. "Esophagogastric Junction Contractility Integral Reflect the Anti-reflux Barrier Dysfunction in Patients with Gastroesophageal Reflux Disease." Journal of neurogastroenterology and motility vol. 23,1 (2017): 27-33. doi: https://doi.org/10.5056/jnm16008
Xie C, Wang J, Li Y, Tan N, Cui Y, Chen M, Xiao Y. Esophagogastric Junction Contractility Integral Reflect the Anti-reflux Barrier Dysfunction in Patients with Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2017 Jan 30;23(1):27-33. doi: 10.5056/jnm16008. PMID: 27426485; PMCID: PMC5216631.
Copy Download .nbib Format: NLM
Upper gastrointestinal complications induced by anti-platelet agents.

Clinical journal of gastroenterology

Kawai T, Sugimoto H, Fukuzawa M, Fukuzawa M, Kusano C, Gotoda T, Moriyasu F.
PMID: 26181729
Clin J Gastroenterol. 2013 Aug;6(4):264-8. doi: 10.1007/s12328-013-0409-7. Epub 2013 Aug 13.

Low-dose aspirin and thienopyridine are associated with gastrointestinal (GI) complications such as petechiae, erosion, ulcer, bleeding, and perforation. The incidence of GI bleeding in aspirin study groups was 0.82 % in the hypertension optimal treatment (HOT) study and 0.76...

Cite
Kawai T, Sugimoto H, Fukuzawa M, et al. Upper gastrointestinal complications induced by anti-platelet agents. Clin J Gastroenterol. 2013;6(4):264-8doi: 10.1007/s12328-013-0409-7.
Kawai, T., Sugimoto, H., Fukuzawa, M., Fukuzawa, M., Kusano, C., Gotoda, T., & Moriyasu, F. (2013). Upper gastrointestinal complications induced by anti-platelet agents. Clinical journal of gastroenterology, 6(4), 264-8. https://doi.org/10.1007/s12328-013-0409-7
Kawai, Takashi, et al. "Upper gastrointestinal complications induced by anti-platelet agents." Clinical journal of gastroenterology vol. 6,4 (2013): 264-8. doi: https://doi.org/10.1007/s12328-013-0409-7
Kawai T, Sugimoto H, Fukuzawa M, Fukuzawa M, Kusano C, Gotoda T, Moriyasu F. Upper gastrointestinal complications induced by anti-platelet agents. Clin J Gastroenterol. 2013 Aug;6(4):264-8. doi: 10.1007/s12328-013-0409-7. Epub 2013 Aug 13. PMID: 26181729.
Copy Download .nbib Format: NLM
Efficacy of DA-9701 (Motilitone) in Functional Dyspepsia Compared to Pantoprazole: A Multicenter, Randomized, Double-blind, Non-inferiority Study.

Journal of neurogastroenterology and motility

Jung HK, Lee KJ, Choi MG, Park H, Lee JS, Rhee PL, Kim N, Park K, Choi SC, Lee OY, Huh KC, Song GA, Hong SJ, Sohn CI, Jung HY, Lee YC, Rew JS, Jee SR, Kwon JG.
PMID: 26811504
J Neurogastroenterol Motil. 2016 Apr 30;22(2):254-63. doi: 10.5056/jnm15178.

BACKGROUND/AIMS: The effect of proton pump inhibitors (PPI) in Asian functional dyspepsia (FD) patients has not been well established as in Westerncountries. DA-9701, a novel prokinetic agent, stimulates gastric emptying and modulates visceral hypersensitivity in vivo and in human...

Cite
Jung HK, Lee KJ, Choi MG, et al. Efficacy of DA-9701 (Motilitone) in Functional Dyspepsia Compared to Pantoprazole: A Multicenter, Randomized, Double-blind, Non-inferiority Study. J Neurogastroenterol Motil. 2016;22(2):254-63doi: 10.5056/jnm15178.
Jung, H. K., Lee, K. J., Choi, M. G., Park, H., Lee, J. S., Rhee, P. L., Kim, N., Park, K., Choi, S. C., Lee, O. Y., Huh, K. C., Song, G. A., Hong, S. J., Sohn, C. I., Jung, H. Y., Lee, Y. C., Rew, J. S., Jee, S. R., & Kwon, J. G. (2016). Efficacy of DA-9701 (Motilitone) in Functional Dyspepsia Compared to Pantoprazole: A Multicenter, Randomized, Double-blind, Non-inferiority Study. Journal of neurogastroenterology and motility, 22(2), 254-63. https://doi.org/10.5056/jnm15178
Jung, Hye-Kyung, et al. "Efficacy of DA-9701 (Motilitone) in Functional Dyspepsia Compared to Pantoprazole: A Multicenter, Randomized, Double-blind, Non-inferiority Study." Journal of neurogastroenterology and motility vol. 22,2 (2016): 254-63. doi: https://doi.org/10.5056/jnm15178
Jung HK, Lee KJ, Choi MG, Park H, Lee JS, Rhee PL, Kim N, Park K, Choi SC, Lee OY, Huh KC, Song GA, Hong SJ, Sohn CI, Jung HY, Lee YC, Rew JS, Jee SR, Kwon JG. Efficacy of DA-9701 (Motilitone) in Functional Dyspepsia Compared to Pantoprazole: A Multicenter, Randomized, Double-blind, Non-inferiority Study. J Neurogastroenterol Motil. 2016 Apr 30;22(2):254-63. doi: 10.5056/jnm15178. PMID: 26811504; PMCID: PMC4819864.
Copy Download .nbib Format: NLM
Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy.

Therapeutics and clinical risk management

Wang ZY, Chen M, Zhu LL, Yu LS, Zeng S, Xiang MX, Zhou Q.
PMID: 25848291
Ther Clin Risk Manag. 2015 Mar 19;11:449-67. doi: 10.2147/TCRM.S80437. eCollection 2015.

BACKGROUND: Coprescribing of clopidogrel and other drugs is common. Available reviews have addressed the drug-drug interactions (DDIs) when clopidogrel is as an object drug, or focused on combination use of clopidogrel and a special class of drugs. Clinicians may...

Cite
Wang ZY, Chen M, Zhu LL, et al. Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Ther Clin Risk Manag. 2015;11:449-67doi: 10.2147/TCRM.S80437.
Wang, Z. Y., Chen, M., Zhu, L. L., Yu, L. S., Zeng, S., Xiang, M. X., & Zhou, Q. (2015). Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Therapeutics and clinical risk management, 11449-67. https://doi.org/10.2147/TCRM.S80437
Wang, Zhi-Yu, et al. "Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy." Therapeutics and clinical risk management vol. 11 (2015): 449-67. doi: https://doi.org/10.2147/TCRM.S80437
Wang ZY, Chen M, Zhu LL, Yu LS, Zeng S, Xiang MX, Zhou Q. Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Ther Clin Risk Manag. 2015 Mar 19;11:449-67. doi: 10.2147/TCRM.S80437. eCollection 2015. PMID: 25848291; PMCID: PMC4373598.
Copy Download .nbib Format: NLM
Absence of esophageal eosinophilia in a toddler with severe eosinophilic esophagitis.

Asia Pacific allergy

Loh W, Wright KM, Chiou FK.
PMID: 29094023
Asia Pac Allergy. 2017 Oct;7(4):243-246. doi: 10.5415/apallergy.2017.7.4.243. Epub 2017 Oct 19.

Eosinophilic esophagitis (EoE) is a clinicopathologic disease characterised by esophageal dysfunction and eosinophil-predominant inflammation. Diagnosing EoE in children is particularly challenging as they tend to present with nonspecific symptoms and their mucosal specimens may have less than the threshold...

Cite
Loh W, Wright KM, Chiou FK. Absence of esophageal eosinophilia in a toddler with severe eosinophilic esophagitis. Asia Pac Allergy. 2017;7(4):243-246doi: 10.5415/apallergy.2017.7.4.243.
Loh, W., Wright, K. M., & Chiou, F. K. (2017). Absence of esophageal eosinophilia in a toddler with severe eosinophilic esophagitis. Asia Pacific allergy, 7(4), 243-246. https://doi.org/10.5415/apallergy.2017.7.4.243
Loh, Wenyin, et al. "Absence of esophageal eosinophilia in a toddler with severe eosinophilic esophagitis." Asia Pacific allergy vol. 7,4 (2017): 243-246. doi: https://doi.org/10.5415/apallergy.2017.7.4.243
Loh W, Wright KM, Chiou FK. Absence of esophageal eosinophilia in a toddler with severe eosinophilic esophagitis. Asia Pac Allergy. 2017 Oct;7(4):243-246. doi: 10.5415/apallergy.2017.7.4.243. Epub 2017 Oct 19. PMID: 29094023; PMCID: PMC5663753.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 1722 entries